Trial · NCT02498652
Results by group95
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 95
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Treatment A2b | 827 | Standard Error 136 | Percentage (%) Change | |
| Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Treatment R1 | 310 | Standard Error 55.5 | Percentage (%) Change | |
| Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Treatment R3 | 311 | Standard Error 51.8 | Percentage (%) Change | |
| Cohort 1 - Renal Hypoxanthine Excretion at 0-24hr of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (AeHXO, CB (%)) | Treatment R5 | 305 | Standard Error 54.7 | Percentage (%) Change | |
| Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment A1 | -39.3 | Standard Error 1.78 | Maximum Percentage (%) Change | |
| Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment A2q | -54.4 | Standard Error 4.50 | Maximum Percentage (%) Change | |
| Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment A2b | -50.3 | Standard Error 4.15 | Maximum Percentage (%) Change | |
| Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment R2 | -57.8 | Standard Error 1.61 | Maximum Percentage (%) Change | |
| Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment R4 | -66.0 | Standard Error 1.86 | Maximum Percentage (%) Change | |
| Cohort 2 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) | Treatment R6 | -73.2 | Standard Error 1.75 | Maximum Percentage (%) Change | |
| Maximum Observed Concentration (Cmax) | Treatment A1 | 1.18 | 95% Confidence Interval 1.03 to 1.36 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment A2q | 2.43 | 95% Confidence Interval 1.94 to 3.04 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment A2b | 1.19 | 95% Confidence Interval 0.997 to 1.42 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment R1 | 1.16 | 95% Confidence Interval 0.911 to 1.47 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment R2 | 1.16 | 95% Confidence Interval 0.937 to 1.43 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment R3 | 1.14 | 95% Confidence Interval 0.905 to 1.44 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment R4 | 1.11 | 95% Confidence Interval 0.928 to 1.33 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment R5 | 1.12 | 95% Confidence Interval 0.877 to 1.44 | µg/mL | |
| Maximum Observed Concentration (Cmax) | Treatment R6 | 1.26 | 95% Confidence Interval 1.02 to 1.56 | µg/mL | |
| Time of Occurrence of Maximum Observed Concentration (Tmax) | Treatment A1 | 1.50 | 95% Confidence Interval 0.500 to 6.02 | hr |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02498652/results?page=2